Your browser doesn't support javascript.
Trends in naloxone prescribed at emergency department discharge: A national analysis (2012-2019).
Ramdin, Christine; Chandran, Kira; Nelson, Lewis; Mazer-Amirshahi, Maryann.
  • Ramdin C; Rutgers New Jersey Medical School, Department of Emergency Medicine, United States. Electronic address: cramdin@njms.rutgers.edu.
  • Chandran K; Georgetown University, School of Medicine, United States.
  • Nelson L; Rutgers New Jersey Medical School, Department of Emergency Medicine, United States.
  • Mazer-Amirshahi M; Georgetown University, School of Medicine, United States; Department of Emergency Medicine, MedStar Washington Hospital Center, United States.
Am J Emerg Med ; 65: 162-167, 2023 03.
Article in English | MEDLINE | ID: covidwho-2209666
ABSTRACT

BACKGROUND:

While having access to naloxone is recommended for patients at risk for opioid overdose, little is known about trends in national naloxone prescribing rates in emergency departments (EDs) both for co-prescription with opioids and for patients who presented with opioid abuse or overdose. This study aims to evaluate the change in naloxone prescribing and opioid/naloxone co-prescribing at discharge using national data.

METHODS:

We conducted an IRB exempt retrospective review of data collected by the National Hospital Ambulatory Medical Care Survey from 2012 to 2019. The primary outcome was trend in rate of naloxone prescribing at discharge from ED visits. We also computed the proportion of visits where naloxone was both administered in the ED and prescribed at discharge, where naloxone and opioids were co-prescribed at discharge, and where an opioid was administered during the ED visit and naloxone was prescribed at discharge. All data were summarized using descriptive statistics and Spearman's Rho (SR) or Pearson's correlation (PR) were used to describe trends.

RESULTS:

There was an estimated total of 250,365 patient visits where naloxone was prescribed at discharge with an increasing rate over time (0% of all ED visits in 2012 to 0.075% in 2019, p = 0.002). There were also increases in naloxone being both administered in the ED and prescribed at discharge (PC 0.8, p = 0.02) as well as in naloxone and opioid co-prescribing (SR 0.76, P = 0.03). There was an increase in utilization of opioids during the ED visit and naloxone prescribing at discharge for the same visit (SR 0.80, p = 0.02).

CONCLUSION:

There are increases in naloxone prescribing at discharge, naloxone and opioid co-prescribing, and opioid utilization during the same visit where naloxone is prescribed at discharge. Future studies should be done to confirm such trends, and targeted interventions should be put into place to increase access to this life-saving antidote.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Naloxone / Opioid-Related Disorders Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Am J Emerg Med Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Naloxone / Opioid-Related Disorders Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Am J Emerg Med Year: 2023 Document Type: Article